Legal status of BPC-157
Prescribing, pharmacy compounding and FDA approval involve separate decisions. A change to a nomination table answers only part of the access question.
What a prescription request means today
Your first question may be simple: can a pharmacy fill a BPC-157 prescription now? BPC-157 care through Promise Peptides (mypromise.com) requires a prescription from a U.S.-licensed clinician. A provider checks each request and makes the prescribing decision; some people won't qualify. Care is limited to U.S. patients, and access depends on state and treatment. Compounded medications have no FDA approval.
FDA's calendar described an advisory discussion about raw drug ingredients, including BPC-157 and TB-500 [21][24]. The 503A rule covers a state-licensed pharmacy making medicine for one named patient. FDA advisers give an opinion, but the agency makes the rule [20][21]. These cited FDA pages do not establish a final decision about the 503A list. An advisory agenda does not grant pharmacies permission.
FDA's withdrawn-nominations table
On FDA's page current as of April 22, 2026, both BPC-157 free base and BPC-157 acetate appear under Bulk drug substances nominated but withdrawn, outside Category 2. The agency previously placed both forms in Category 2. The free base is the plain ingredient; acetate is a salt form.
The withdrawal ends evaluation of those nominations for the 503A list. It does not approve BPC-157 or authorize a pharmacy to compound it. FDA publishes no removal date that would support assigning the table change to a particular month.
I attach more significance to the remaining ingredient requirements than to the reassuring sound of withdrawn. Those requirements still govern what a pharmacy may prepare.
Published safety concerns
FDA's significant-safety-risk page records concerns about immune reactions for some routes of administration, peptide-related impurities and difficulties characterizing the ingredient. The free-base and acetate entries share the underlying concern; the record establishes no safer form.
The safety rationale remains published alongside the later withdrawn-nomination status. A table's administrative category and the biological questions can change on different tracks.
Pharmacy requirements
Under the 503A framework, a state-licensed pharmacy prepares medicine for a named patient on a valid prescription, subject to bulk-ingredient eligibility and other requirements. A 503B outsourcing facility is FDA-registered and may prepare larger batches for clinics, also under applicable requirements.
A licensed provider decides whether to prescribe. The pharmacy then has separate legal requirements to satisfy. A telehealth visit can provide clinical review, while leaving the ingredient rules in place. Compounded medicines are not FDA-approved.
The advisory committee record
The cited July 23-24, 2026 advisory-committee calendar entry listed BPC-157 for discussion about inclusion on the 503A Bulks List. The interim-policy guidance page describes the broader framework.
An advisory committee offers advice; FDA makes the agency's final decision. The cited record does not establish a final listing decision. The agenda by itself grants no compounding permission.
Competitive sport
The World Anti-Doping Agency prohibits BPC-157 at all times under its S0 category for non-approved substances. That sport rule operates separately from a provider's prescribing decision and the pharmacy framework.
A question about whether a particular test detects it is a different question again. The drug-testing FAQ explains the limits of the cited record without inventing a detection window.